Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAVES: EchiTabPlus-ICP vs FAV-Africa for Snakebite Envenoming
NCT02694952Phase 3Withdrawn
- Sponsor
- Illumina
- Start
- Mar 2016
- Primary completion
- Jun 2016
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Anti-infectious Disease mAbs
01
Overview
A Phase 3 trial of EchiTAb Plus in snakebite envenoming, sponsored by Illumina. Planned start Mar 2016; status: withdrawn.
02
Drugs
EchiTAb Plus
03
Conditions
snakebite envenoming
Beyond the preview
Go deeper on NCT02694952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02694952.